Sign In
Buy LLY
$1,192.80
+22.94 (+1.96%)
At Close: Aug 06, 2026
Eli Lilly CEO David Ricks on Q2 earnings, obesity pill late-stage trial results
08:12am, Thursday, 07'th Aug 2025
CNBC's Angelica Peebles and Eli Lilly chairman and CEO David Ricks join 'Squawk Box' to discuss the company's quarterly earnings results, late-stage trial data on its experimental obesity pill orforgl
Eli Lilly's obesity pill led to around 12% weight loss in late-stage trial, paving way for approval
08:09am, Thursday, 07'th Aug 2025
CNBC's Angelica Peebles joins 'Squawk Box' with the latest news from Eli Lilly.
Novo Nordisk shares jump as Eli Lilly's weight-loss pill data disappoints
07:50am, Thursday, 07'th Aug 2025
Shares in Novo Nordisk rose 13.6% on Thursday after trial data from Eli Lilly's experimental weight-loss pill fell short of expectations, boosting investor confidence in the Danish drugmaker's market-
Eli Lilly's oral weight-loss pill didn't work so well, and the stock is plunging
07:01am, Thursday, 07'th Aug 2025
Stock was heading for biggest one-day selloff in 26 years
Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar
06:54am, Thursday, 07'th Aug 2025
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. Eli Lilly also released long-awaited lat
Eli Lilly raises full-year profit forecast on weight-loss drug strength
06:52am, Thursday, 07'th Aug 2025
Eli Lilly raised its full-year profit forecast on Thursday, betting on surging demand for its blockbuster weight-loss drug, Zepbound, as it targets new markets and looks to grab more share from Novo N
Lilly reports second-quarter 2025 financial results and raises guidance
06:45am, Thursday, 07'th Aug 2025
Revenue in Q2 2025 increased 38% to $15.56 billion driven by volume growth from Zepbound and Mounjaro. Increased the midpoint of our 2025 full-year revenue guidance by $1.5 billion to be in the range
These Stocks Are Moving the Most Today: Fortinet, AppLovin, Eli Lilly, Airbnb, Duolingo, and More
06:05am, Thursday, 07'th Aug 2025
A slew or company results were causing big market moves ahead of the opening bell Thursday, and for many, earnings-beat wasn't enough to prevent a selloff.
Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday
04:34pm, Wednesday, 06'th Aug 2025
Lilly's shot Zepbound has seized a commanding majority of U.S. obesity prescriptions.
How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings
07:41am, Wednesday, 06'th Aug 2025
Eli Lilly and Company LLY will release earnings results for the second quarter before the opening bell on Thursday, Aug. 7.
Wall Street Breakfast Podcast: Novo Nordisk Trims Outlook On Rising Rivalry
06:47am, Wednesday, 06'th Aug 2025
Novo Nordisk cuts costs and lowers 2025 sales outlook due to increased competition and slower Wegovy growth, impacting its market value. Disney's ESPN strikes a non-binding deal to acquire NFL media a
Novo Nordisk Stock Catches a Downgrade. The Eli Lilly Threat Is Just One Reason.
11:15am, Tuesday, 05'th Aug 2025
Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by its U.S. rival.
Eli Lilly: Sell LLY Stock Ahead of Its Earnings?
07:45am, Tuesday, 05'th Aug 2025
Eli Lilly (NYSE:LLY) is set to release its earnings on Thursday, August 7, 2025. In the past, Eli Lilly's stock has displayed a pattern of negative one-day returns following earnings announcements.
Eli Lilly Reverses Early Weakness, Closes Near Day's High After Key Trading Signal
07:03am, Tuesday, 05'th Aug 2025
LLY reverses early weakness and climbs 1.8%
Prediction: This Unstoppable Growth Stock Will Be Worth $2 Trillion in the Next 7 Years
08:33pm, Monday, 04'th Aug 2025
Eli Lilly (LLY 0.73%) has been a terrific investment in recent years. Thanks to significant clinical progress and outstanding financial results, the company has become the largest healthcare player in
